Criminal Identification Software Service

This painting company has been stable, but they have seen sustained growth and have been one of the fastest growing small business painting companies in the Vancouver/Portland area. Starting in 2013, annual had already eclipsed half a million by 2019. With a work-from-home office, this business provides the ability to manage safely out of your own home or to be able to choose your ideal location to rent. Strong customer ratings and consistently high levels of service have made this an ideal business for anyone looking to establish a presence in the painting industry or to expand your current painting business territory and customer base. Detailed Information Employees:2 FTE Support & Training: Seller will negotiate a transition period Reason for Selling: Relocation

An exceptional opportunity to acquire a leading International Early Childhood Development Company, renowned for its pioneering integration of digital content in early childhood education, with a strong emphasis on social, emotional, and intellectual development. Programs are offered in more than 20 languages and have an impressive presence in more than 30 countries. The Company’s solid track record of meeting demand and creating growth is backed by an extensive franchise/license network. The Company’s proven teaching models produce exceptional results that have garnered high satisfaction ratings among children and parents alike. Independent research validates the superior outcomes achieved through exclusive age-based programs, enabling children to accelerate their learning levels twice as fast as their peers. The foundation of the Company’s success lies in its Licensing and Master Franchise structure. This highly effective framework enables them to meet local needs and rise above competition; adapting to diverse regional markets, and catering to cultural nuances. With plans for further expansion, the Company is poised to strengthen its position as a global leader in education. The Company has taken intellectual property protection seriously, employing robust safeguards to protect its 95 international trademarks, and 49+ copyrights, via a fortified software registration system. Don't miss this rare opportunity to acquire a thriving global Education Company with a proven model, and a commitment to innovation. Seize the chance to make a profound impact on children's lives while unlocking unlimited potential for growth and success. NDA is required 626to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Facilities: No facilities. It is all virtual. Competition: While operating in a fragmented industry with numerous competitors, what truly distinguishes this Company is its dedication to cultivating essential learning skills that can be universally applied across academic subjects, such as mathematics. By combining digital resources, interactive technology, curriculum development, and effective teaching methods, the Company has long been at the forefront of integrating digital content into early childhood learning. The result is consistently achieving remarkable outcomes and staying ahead of any competitor. Growth & Expansion: Numerous avenues for growth and expansion lie ahead, including: 1. Expand presence by appointing Master Franchisees in Latin America, Asia, and Africa. 2. Strengthen market coverage by adding franchisees to existing geographic territories. 3. Boost brand visibility through enhanced social media marketing strategies. 4. Enhance the current digital curriculum in alignment with the newest and most advanced technology platforms. 5. Explore opportunities to directly sell to US Schools, tapping into a mass market segment. 6. Capitalize on the demand for digital content by offering valuable resources to families. By pursuing these strategic initiatives, the Company can harness its potential for exponential growth and secure a prominent position in the industry. Financing: TBD if deal structure and terms are acceptable. Support & Training: To facilitate a seamless transition and ensure continued success, the Seller is committed to providing comprehensive training and is open to the possibility of remaining as an employee, subject to negotiation regarding salary, duration, and terms. Reason for Selling: The Seller believes that now is an opportune time to sell.

Our client is a world leader in iris recognition technology with a large production capacity based in USA. They are a multinational corporation with a robust track record of selling its best-selling, award winning technology products worldwide. Clients include the UN, the US Department of Homeland Security, US Navy, US Marine Corps, the governments of India the Philippines, Kenya, and in the private Sector Northrop Grumman, InCadence and numerous others. The company has and continues to develop an ever-increasing range of technical applications for its products in a very large and rapidly growing market. Applications range from numerous physical security applications to blockchain and cryptocurrency applications. This firm owns 28 patents (24 registered and 4 pending) for its proprietary "iris matching algorithm, iris recognition in bright outdoors under sunlight" technology and security technology. Our client also has world-leading iris recognition technology to crypto wallet, which dramatically improves the security and convenience of digital assets on blockchain. In addition to multiple patents, our client also owns 10 trademarks. Our client's iris recognition algorithm was evaluated as the world's best technology at IREX I of NIST in the USA, and its excellence has been proven. They are one of few companies to provide a complete solution including SW and HW from iris image scanner to matching SDK on server with the world's best technology. This business has global references for the National ID projects of the Indian and Philippine governments They achieved the No.1 market share, including UN-affiliated organizations such as UNHCR and WFP, and these markets are expanding worldwide. Our client's tech and related device is the only iris camera system satisfying MOSIP SBI 2.0 requirements for authentication (many countries are utilizing the MOSIP platform for their National ID systems). Our client's unique and powerful technologies are registered and protected by global patents, enabling stable business development and expansion. The company offers a total data infrastructure solution (large or small data requirements) for Web 3.0 (Web 3.0 is the approach for a new iteration of the World Wide Web which incorporates concepts such as decentralization, blockchain technologies, and token-based economics). Their technologies are based on Blockchain, IPFS, and distributed storage of private keys (IPFS is a distributed file system that seeks to connect all computing devices with the same system of files. This means data can be securely shared for Know Your Customer and Anti-Money Laundering (KYC and AML) needs. This meets information sharing protocols between service providers and will lead to a new and open data economy. The ramifications are complete security for Bank information, Financial Transaction Data, Driving Data, SNS Contents, Health Information, Government/Education Certification, Insurance Information in short data stemming from virtually any source. Confidential Information Memorandum (CIM) is available upon receipt of our short online NDA. Financing: If the price and deal structure is right. Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: World-wide expansion

Our client sources an excellent quality bourbon that has a higher yield than a traditional 6-8-year aged bourbon. Due to the higher yield because of less evaporation, they are able to keep the MSRP very competitive and are growing rapidly. They partner with a smaller craft distillery as their co-packer in order to keep production costs down. The founder is a rising, Tennessee-based singer/songwriter with thousands of followers. He uses, and will continue to use, his social media and concerts to publicize the bourbon and allows fans to become partial minority owners of the brand, thus far garnering approximately $200,000 as of the beginning of December 2022. Since the launch of the bourbon brand in 2018 it has earned some of the largest and most prestigious awards which can be awarded in the spirit industry. 1) Named Top 6 in the World in Forbes 2) Featured in Billboard, Rolling Stone, Uproxx, American Songwriter 3) Platinum Los Angeles 4) Double Gold San Francisco (largest award in the world for whiskey to earn) 5) Double Gold New York International 6) Double Gold New York Best Fifty 7) Gold Las Vegas 8) Silver Denver Our client has created a supportive community of real fans who love both the founder's music and the bourbon. Our client has taken the brand as far as 26 states. They will soon expand into Canada and exporting to South Africa & Vietnam is on the horizon. The founder and his partner are willing to stay on the team to bring the Bourbon brand to a much higher national level with a well-capitalized strategic buyer or owner-operator who is passionate about the bourbon industry. An NDA is required to secure a comprehensive Confidential Information Memorandum (CIM). Growth & Expansion: In CIM - NDA Required. Financing: If the price and deal structure is right Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: Other Projects

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

The Company operates in the healthcare technology space with a focus on addressing gaps in dementia and Alzheimer’s care. The company has built an ecosystem where data is collected from caregivers and patients in real-time and pushed into physicians’ EHR/EMR systems to monitor the effectiveness of the prescribed treatment plan. Alzheimer’s Disease and other dementia is the first condition that the platform will be focused on. Its platform supports physicians in managing patients through tools that enable remote monitoring and data collection, allowing for more continuous oversight rather than episodic intervention. The business generates revenue through a combination of public healthcare reimbursements and collaborations with pharmaceutical and research entities. Its model emphasizes integrating digital health solutions into clinical workflows to improve patient tracking and care coordination. The Company’s target users include healthcare providers, caregivers, and researchers working with aging populations impacted by cognitive decline. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .